Cardiovascular Diseases
Syngeneic models for checkpoint inhibitor efficacy, immune cell profiling, cell-based assays, target engagement, and translational biomarkers.
Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide and are often interconnected with metabolic and renal disorders. Aragen offers a range of clinically relevant cardiovascular and thrombosis models to support the evaluation of novel therapeutics targeting pulmonary hypertension, cardiac remodeling, thrombosis, coagulation disorders, bleeding, and platelet dysfunction. These models enable comprehensive assessment of efficacy, mechanism of action, biomarkers, and translational outcomes for drug discovery and development
Available Cardiovascular Disease Models
- Monocrotaline-Induced Pulmonary Arterial Hypertension (PAH): A well-established model for studying pulmonary vascular remodeling, right ventricular hypertrophy, and pulmonary hypertension.
- Isoprenaline-Induced Cardiac Fibrosis in Rats: Mimics cardiac injury and fibrosis, enabling evaluation of anti-fibrotic and cardioprotective therapies.
- Stenosis + FeCl₃-Induced Thrombosis Model: A robust thrombosis model for assessing antithrombotic agents and vascular injury-related clot formation.
- Coagulopathy Models: Induced using Factor Xa inhibitors, thrombin inhibitors, and platelet aggregation inhibitors to evaluate anticoagulant and hemostatic therapies.
- Liver Laceration Hemorrhagic Shock Model in Rats: A clinically relevant bleeding model for studying hemorrhage, resuscitation strategies, and hemostatic interventions.
- Busulphan-Induced Thrombocytopenia in Rats: A platelet-depletion model used for evaluating therapies targeting thrombocytopenia and platelet recovery.
These validated models provide translational platforms for investigating cardiovascular pathophysiology, thrombosis, coagulation, bleeding disorders, and therapeutic efficacy across a broad spectrum of cardiovascular indications
